CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate...
Phase 1
Orlando, Florida, United States
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate...
Phase 1, Phase 2
Orlando, Florida, United States and 25 other locations
agent for use with positron emission tomography (PET) imaging for prostate cancer.The research is being done to study the capabilit ...
Phase 2
Orlando, Florida, United States
Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men wo ...
Phase 1
Orlando, Florida, United States and 25 other locations
Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate...
Phase 3
Orlando, Florida, United States and 51 other locations
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate...
Phase 1, Phase 2
Orlando, Florida, United States and 7 other locations
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Orlando, Florida, United States and 378 other locations
second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate...
Phase 3
Orlando, Florida, United States and 224 other locations
compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate...
Phase 3
Lakeland, Florida, United States and 282 other locations
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or sec...
Phase 3
Orlando, Florida, United States and 164 other locations
Clinical trials
Research sites
Resources
Legal